{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-026953","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2026-06-03T01:32:29+00:00","discovered_at":"2026-06-03T10:05:00.270952+00:00","generated_at":"2026-06-03T10:05:24.948876+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each","bullets":["Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.","Placement agent ThinkEquity receives 7.5% cash fee and 5-year warrants for 72,465 shares at $4.0625.","Net proceeds to be used for working capital, general corporate purposes, and business advancement.","Offering closed June 2, 2026; shares issued under effective shelf registration statement (Form S-3)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026953","json":"https://secwatch.observer/filing/0001493152-26-026953.json","markdown":"https://secwatch.observer/filing/0001493152-26-026953.md","text":"https://secwatch.observer/filing/0001493152-26-026953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226026953/0001493152-26-026953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226026953/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:05:24.948876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e449b2786c999d8fa41aae0cb1c33327dad84d3","claim":"BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $4.71 million (effective 2026-05-31).","evidence_excerpt":"On May 31, 2026, BriaCell Therapeutics Corp. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with ThinkEquity LLC","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226026953/0001493152-26-026953-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"ThinkEquity LLC"},{"label":"Value","value":"$4.71 million"},{"label":"Effective","value":"2026-05-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}